Bristol Tequin Labeling Update Includes New Indication, Glucose Warning
Executive Summary
A supplemental approval for Bristol-Myers Squibb's Tequin adds an indication for uncomplicated skin and skin structure infections - but also adds language on QT prolongation and blood glucose disturbances
You may also be interested in...
Tequin Labeling Notes In Vitro Activity Vs. Penicillin-Resistant S. Pneumoniae
Labeling for Bristol-Myers Squibb's Tequin discusses the in vitro efficacy of the quinolone antibiotic against penicillin-resistant Streptococcus pneumoniae.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials